The Journal of Sexual Medicine released a study in May finding that patients who had transvaginal mesh operations experienced diminished sexual function after the procedure. The research was conducted in Taiwan at the Kaohsiung Medical University by Cheng-Yu Long, M.D., Ph.D. and colleagues. The authors of the study encouraged physicians to advise women with pelvic organ prolapse of the risk before surgery, as reported in MD News.
Transvaginal mesh has been used by surgeons to treat women with pelvic organ prolapse (POP) and stress urinary incontinence (SUI). The U.S. FDA has previously warned that women treated with transvaginal mesh suffer more complications than those who receive traditional surgical repair. The FDA advised that transvaginal mesh may result in bleeding, infection, pain, organ perforation, urinary problems or erosion of the vaginal mesh itself.
The Food and Drug Administration ordered the makers of the surgical mesh products to conduct further study concerning the safety of their products. The FDA has not yet decided to issue a general recall of the trans-vaginal products.